A Chinese research team has reported a microfluidic approach to boost CD19 CAR-T cell transduction at low viral doses, aiming to reduce manufacturing bottlenecks for CAR-T programs. The work focuses on compressing manufacturing timeline steps by improving efficiency of transduction under limiting conditions. For CAR-T developers, transduction efficiency directly impacts vector usage, turnaround time, cost, and consistency across manufacturing lots. A method that maintains performance at lower viral doses can also reduce cost-of-goods constraints, potentially improving scalability. If the approach holds up in broader process-transfer and clinical-grade settings, it could become a template for next-generation manufacturing process engineering.